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Abstract 
Background: Missense variants in the ryanodine receptor 1 gene (RYR1) are associated 
with malignant hyperthermia but only a minority of these have met criteria for use in 
predictive DNA diagnosis. We examined the utility of a simplified method of segregation 
analysis and a functional assay for determining the pathogenicity of recurrent RYR1 variants 
associated with malignant hyperthermia. 
Methods: We identified previously uncharacterised RYR1 variants found in 4 or more 
malignant hyperthermia families and conducted simplified segregation analyses. An efficient 
cloning and mutagenesis strategy was used to express ryanodine receptor protein 
containing one of six RYR1 variants in HEK293 cells. Caffeine-induced calcium release, 
measured using a fluorescent calcium indicator, was compared in cells expressing each 
variant to that in cells expressing wild type ryanodine receptor protein.  
Results: We identified 43 malignant hyperthermia families carrying one of the six RYR1 
variants. There was segregation of genotype with the malignant hyperthermia susceptibility 
phenotype in families carrying the p.E3104K and p.D3986E variants but the number of 
informative meioses limited the statistical significance of the associations. HEK293 functional 
assays demonstrated an increased sensitivity of RyR1 channels containing the p.R2336H, 
p.R2355W, p.E3104K, p.G3990V and p.V4849I compared to wild type but cells expressing 
p.D3986E had a similar caffeine sensitivity to cells expressing wild type RyR1.  
Conclusions: Segregation analysis is of limited value in assessing pathogenicity of RYR1 
variants in malignant hyperthermia. Functional analyses in HEK293 cells provided evidence 
to support the use of p.R2336H, p.R2355W, p.E3104K, p.G3990V and p.V4849I for 
diagnostic purposes but not p.D3986E.  
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Malignant hyperthermia (MH) is a rare, pharmacogenetic disorder triggered in susceptible 
individuals upon exposure to volatile anaesthetics and depolarizing neuromuscular blocking 
drugs1.  Upon triggering, patients suffer a hypermetabolic reaction caused by failure to 
regulate calcium homeostasis in skeletal muscle.  The type I ryanodine receptor gene 
(RYR1) is the primary locus for MH with 189 variants in the coding sequence identified in 
association with the disease (www.emhg.org).  Despite this, MH is a heterogeneous disorder 
with several other loci implicated: mutations have been identified in CACNA1S 2-4, which 
encodes the alpha 1 subunit of the dihydropyridine receptor, Cav1.1. Most recently 
homozygosity for p. W284S in STAC3 has been implicated in Native American myopathy, 
which is associated with MH 5.  There remains a significant minority of cases, however, in 
which no mutation is found in RYR1, CACNA1S or STAC3.  Our group and others are using 
next generation sequencing to identify variants in these genes and novel genes potentially 
implicated in susceptibility to MH 6-9 and this is generating a large number of variants of 
uncertain significance.  The European Malignant Hyperthermia Group (EMHG) established a 
set of criteria that variants associated with MH should meet before they can be included onto 
the genetic diagnostic panel for MH 10.  If patients are found to possess a variant meeting 
these criteria, they can be diagnosed at high risk of developing MH under anaesthesia. If no 
such variant is found, diagnosis requires a muscle biopsy and subsequent in vitro 
contracture tests (IVCT) for diagnosis 10. To comply with the EMHG guidelines, variants have 
to be functionally characterized.  For RYR1 variants, the coding region of 15 kb makes the 
cloning of full length RYR1 mutant constructs and subsequent transduction of muscle cell 
lines technically challenging, time-consuming and costly.   None of the published 
experimental models for functional analysis of RYR1 variants is ideal but the most frequently 
used is heterologous expression in HEK293 cells 11-13. This system is not ideal because 
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RyR1 normally functions in the architecturally complex environment of skeletal muscle and in 
the presence of numerous accessory proteins not expressed in other cell types, including 
HEK293 cells. In the absence of an ideal system for the functional characterization of RYR1 
variants, the expert consensus of the EMHG, in formulating its guidelines,10 was to accept 
pragmatically the use of heterologous expression in HEK293 cells along with other imperfect 
models. 
 
A consequence of the constraints on functional analysis of RYR1 variants is that only 34 
variants have been added to the diagnostic panel out of 189 reported to be associated with 
MH susceptibility (www.emhg.org).  Urwyler and colleagues 14 proposed the use of linkage 
analysis as an alternative means of assessing likely pathogenicity. The requirement for a 
specialized invasive procedure (muscle biopsy and IVCT) for accurate phenotyping and the 
lack of validity in combining families for linkage in a heterogeneous disorder has meant this 
is not a realistic option. M¿ller and colleagues 15, however, proposed a simplified method for 
segregation analysis (SISA) where combining the number of informative meioses from more 
than one family carrying the same variant can legitimately be used to generate a probability 
of association between genotype and phenotype. Use of the SISA method has been 
proposed as a tool to identify likely pathogenic variants in generic guidelines for classification 
of genetic variants 16.  
 
The aims of this study are to assess the utility of SISA and functional characterization in 
HEK293 cells for determining the likely pathogenicity of RYR1 variants found in 43 families 
from the UK MH population with a sub aim to determine if there was equipoise between 
different methods of transfecting the HEK293 cells. If these variants were confirmed to be at 
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least likely to be pathogenic, their adoption onto the diagnostic panel for MH would increase 
by up to 14% the number of the >770 families in the UK where DNA diagnostics would be 
applicable.  
 
Methods 
Variant selection and identification of families carrying variants 
We selected RYR1 variants that we had found in 4 or more families in association with MH 
susceptibility but which had not been functionally characterized. We began screening our 
patient resource for RYR1 variants following publication of the first RYR1 variant implicated 
in MH susceptibility 17. As further RYR1 variants were implicated our screening programme 
evolved into a systematic search for all published variants principally using amplification 
refractory mutation system or restriction digest assays. From the early 2000s it became 
economically feasible to use traditional (Sanger) sequencing of mutation Òhot-spotsÓ and 
even the whole coding region of RYR1 and CACNA1S 18. Most recently, next generation 
sequencing (NGS) technology has been employed. We have screened members of 652 
independent MH families for the presence of the variants of interest, using one or more of 
amplification refractory mutation system or restriction endonuclease digest assays, Sanger 
sequencing or NGS. 
 
Segregation analyses 
For each family carrying one of the variants of interest, the number of informative meioses 
was calculated as one less (to account for ascertainment bias) than the number of affected 
carriers (including obligate carriers). The number of informative meioses for all families 
carrying a single variant were summed before calculating the probability that the variant is 
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not disease causing according to M¿ller	and colleagues 15. British/Dutch guidelines 16 have 
suggested that the presence of genotype-phenotype discordance (affected non-carrier or 
non-affected carrier) precludes the use of the SISA method of predicting disease 
association. When we encountered cases of discordance, we reviewed the IVCT records 
(phenotype) and calculated the probability that the IVCT responses represented an 
abnormal response 19. We also verified the genotype using Sanger sequencing where a 
DNA sample was available and, again when feasible, used deep resequencing of RYR1 and 
CACNA1S to look for alternative disease-associated variants in cases of affected non-
carriers. 
 
Cloning  
Human RYR1 cDNA was inserted into a pcDNA3.1 expression vector (containing a 
neomycin resistance gene cassette) to produce pcRYR1 (20,649bp in size) as reported 
previously 12.  Sequences were aligned to the RYR1 reference sequence NM_000540.2 with 
complementary DNA (cDNA) positions 1, 2 and 3 defined as the ATG start codon. pcRYR1 
was split into two roughly equal subclones containing the entire RYR1 coding sequence 
between them.  The 5Õ subclone spanned from a SpeI site within the pcDNA 3.1 backbone to 
the HindIII site at cDNA position 9553. The 3Õ subclone spanned from the Acc65I site at 
cDNA position 6,980 to an XbaI site in the pcDNA 3.1 backbone. Both fragments were 
inserted into a pBluescript SK II + vector to create subclones of 12.523bp and 11,128bp, 
respectively. 
 
These subclones were used for mega primer polymerase chain reaction (PCR) of whole 
plasmid (MEGAWHOP) site-directed mutagenesis as reported previously 20,12.  Briefly, a 
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forward mutagenic primer was paired with a wild type reverse primer to create mega primers 
between 200 bp and 800 bp in length containing the variant.  The mega primers were 
sequenced to confirm the presence of the mutation before using them for whole plasmid 
mutagenesis of one of the subclones using the QuikChange protocol (Agilent Technologies, 
Wokingham, UK).  Mutant subclones were sequenced to confirm successful mutagenesis.  
 
pcDNA 
The p.R2336H, p.E3104K, p.D3986E, p.G3990V and p.V4849I variants in the 3Õ subclone 
were reconstructed into the pcRYR1 plasmid by using the same Acc65I and XbaI sites used 
to create the subclone. 
 
pTUNE 
Wild type, p.R2355W and p.D3986E RYR1 constructs were inserted into a pTUNE inducible 
expression vector 21 using both subclones.  Initially, an endogenous BspEI restriction site 
had to be removed from the pTUNE neomycin resistance gene by digesting with BspEI and 
blunting with DNA polymerase I (Klenow fragment).  The entire 3Õ end of RYR1 was removed 
from wild type, p.R2355W and p.D3986E 3Õ subclone constructs using the same Acc65I 
restriction site that was used for creating the subclone paired with a SalI site downstream of 
the stop codon of RYR1.  This fragment was inserted into the modified pTUNE vector by 
ligation into compatible BsiWI and XhoI restriction sites. The wild type 5Õ subclone fragment 
was removed using the same SpeI restriction site used to create the subclone and the BspEI 
site at cDNA position 7,073.  The 5Õ fragment was inserted into the pTUNE subclone using a 
compatible NheI site for the SpeI site and the BspEI site that was intact in the 3Õ end of 
RYR1 to create full-length pTUNERYR1 (ptRYR1) constructs 27,279bp in size. 
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Cell culture and transfection 
HEK293 cells were maintained according to the supplierÕs (LGC Standards, Teddington, UK) 
recommended conditions (DulbeccoÕs Modified Essential Medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS, Biosera, Uckfield, UK) and 100 units/mL of penicillin and 
100 µg/mL of streptomycin and cultured at 37¡C and 5% CO2 in a humidified incubator).  
Stable transfection of HEK293 cells was performed in 6-well plates.   Transfections were 
performed using Lipofectamine-2000 according to manufacturerÕs instructions. Initial 
selection pressure was performed using 1 mg/mL G418 for 10 days before lowering the 
antibiotic concentration to 400 µL/mL through several rounds of selection until individual 
colonies were selected as stable clones.  Transfected cells were seeded onto entactin-
collagen IV-laminin (ECL) coated 96-well Opti-Clear plates (Corning Incorporated) 24 h prior 
to calcium measurements. 
 
Transient pcRYR1 and pTUNERYR1 transfections were performed on ECL coated 96-well 
Opti-Clear plates that were seeded with HEK293 cells 24 h prior to transfection as described 
above. For pcRYR1 transfections, the medium was changed 6 h after transfection and 
incubated for 48 h prior to calcium imaging.  For ptRYR1 transfections, 6 h post- 
transfection, the medium was changed to one containing 25 µM isopropyl-β-
thiogalactopyranoside (IPTG) to induce a consistent level of RyR1 expression.  Fresh 
medium containing IPTG was added every 24 h and caffeine-induced calcium release 
experiments were performed 72 h post-transfection.   
 
Western blotting 
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Transfected and untransfected HEK293 cells were lysed with 100 mM Tris and 0.5% (v/v) 
Triton X-100.  The supernatant from the cell lysis procedure was isolated and quantified 
using a Bradford assay (Bio-Rad). Fifty µg of whole protein was run on a 4%-8% 
polyacrylamide gel at 100 volts for 2 h. After electrophoresis, the separated protein was 
transferred to a polyvinylidene fluoride (PVDF) membrane overnight at 4¡C.  RyR1 protein 
was detected using a 34C mouse anti-RyR1 primary antibody. The primary antibody was 
detected using a goat-anti-mouse secondary antibody with a horseradish peroxidase (HRP) 
conjugate.  Chemiluminescence was detected using the North2South HRP detection kit 
(Thermo Scientific). 
 
Imaging 
Prior to imaging, transfected cells were washed four times in a RingerÕs solution (125 mM 
NaCl, 5 mM KCl, 2 mM CaCl2, 1.2 mM MgSO4, 6 mM glucose, 25 mM HEPES, pH 7.4) and 
incubated with 20 µM Fluo-4 AM in the dark for 20 min at room temperature (Life 
technologies).  Excess Fluo-4 was washed off an additional four times with RingerÕs solution.  
Caffeine-induced calcium release experiments were performed using the system described 
by Duke and Steele 22.  Briefly, a caffeine dilution series was created in RingerÕs solution. 
Experiments on stable HEK293 cell lines were carried out using 0.5 mM, 1 mM, 2 mM,  5 
mM and 20 mM caffeine.  Experiments on transiently transfected HEK293 cells with the 
p.G3990V construct were performed using  0.2 mM, 0.5 mM, 1 mM, 2 mM, 5 mM, 10 mM 
and 20 mM caffeine.   The remaining transient transfection experiments and all experiments 
involving ptRYR1 constructs were performed using a simplified series of 0.5 mM, 1 mM, 2 
mM, 4 mM, 8 mM and 20 mM caffeine. In all experiments a wild type and untransfected 
(data not shown)	control was included.   Additionally, control experiments were performed to 
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ensure that the difference in caffeine series did not significantly alter the EC50 calculated 
from the data (data not shown).  Each caffeine solution was loaded into a syringe and the 
syringes containing solutions of different caffeine concentration were attached to a central 
column.  Each syringe was under computer control and sequentially injected caffeine at 
standardized levels from the lowest concentration to the highest.  Each dose of caffeine was 
perfused off the cells before the next dose to prevent additional calcium release events due 
to remaining caffeine.   Caffeine-evoked calcium release was observed using confocal 
microscopy as a temporary increase in fluorescence directly after the application of caffeine. 
 
Data handling and analyses 
Simplified segregation analyses were carried out according to M¿ller	and colleagues	15. 
 
In the functional studies, only cells that responded to concentrations of caffeine < 4 mM were 
selected for analysis as a small proportion (average 4%) of untransfected cells responded to 
higher (8 mM-20 mM) concentrations of caffeine.  Videos were imported into ImageJ 
software, responding cells were selected as regions of interest and their fluorescence levels 
over time were plotted using the Prism 6 statistics package.  Each video trace was 
individually normalized with 0 % defined as the level of fluorescence before the addition of 
any caffeine and 100 % defined as the peak fluorescence obtained at that concentration.  
Normalized traces were used to construct concentration-response curves by plotting the 
peak fluorescence generated at each caffeine concentration on a logarithmic scale before 
using the non-linear regression function in Prism 6 to create the curve.  The concentration at 
which half of the maximum response was generated (EC50) was calculated from the 
concentration-response curves.  Data are presented as mean, standard error (SE) and 95% 
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confidence intervals (95% CI). Statistical inference was based on unpaired StudentÕs t-tests, 
using a P value < 0.05 as evidence of statistical significance. 
 
Results 
RYR1 variants 
The following RYR1 variants (n=number of families) met our criteria for inclusion in this 
study: c.7007G>A, p.R2336H (n=8); c.7063C>T, p.R2355W (n=7); c.9310G>A, p.E3104K 
(n=4); c.11958C>G, p.D3986E (n=5); c.11969G>T, p.G3990V (n=11); c.14545G>A, 
p.V4849I (n=8). The evolutionary conservation of the nucleotide and encoded amino acids 
between species and RyR isoforms are shown in supplementary tables 1 and 2 and the 
physicochemical consequences of the amino acid substitutions, and the minor allele 
frequencies of the variants are shown in supplementary table 3.  
 
Segregation analyses 
Table 1 shows the number of families in which the familial variant either segregates 
completely with the MH susceptible phenotype (determined by the in vitro contracture tests 
10) or not. Also presented are the total number of informative meioses in those families 
where there is segregation and, in those families where there is no genotype-phenotype 
discordance, the probability of segregation occurring by chance, both of which were 
calculated according to the SISA method 15 . 
 
There were 8 affected non-carriers in 7 families but no non-affected carriers. The pedigrees 
of these families are shown in supplementary figure 1. Analyses of the in vitro contracture 
responses 19  of the affected non-carriers gave a predicted probability of true susceptibility to 
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MH of > 0.9 in all cases (data not shown). The absence of the familial variant was confirmed 
in the affected non-carriers by sequencing stored DNA in all but one case, where DNA was 
not available (individual IVii in family 1, supplementary figure 1). Sufficient high quality DNA 
was available for deep resequencing of the entire coding sequence of RYR1 and CACNA1S 
in 3 affected non-carriers, one of whom (individual IIIii in family 5, supplementary figure 1) 
was found to harbour a rare RYR1 variant (c.6478G>A, p.G2160S). 
 
Functional studies 
 
Ca2+ Imaging in stably transfected HEK293 cells using pcRYR1 constructs 
Stable HEK293 cell lines were produced for wild type RYR1 and 3 of our 6 RYR1 variants 
(arbitrarily chosen): p.R2336H, p.D3986E and p.G3990V.  Stable cell lines were exposed to 
0.5 mM, 1 mM, 2 mM, 5 mM and 20 mM caffeine and the fluorescence data over time were 
plotted (Figure 1b).  Concentration-response curves for each variant are illustrated in Figure 
1c-e and the EC50 values plotted in Figure 1f. For cells transfected with p.R2336H and 
p.G3990V constructs, the fitted curve was shifted to the left, indicating an increase in 
sensitivity to caffeine.  Compared to cells stably transfected with the wild type pcRYR1 
construct where the mean EC50 was 3.21 mM (95% CI 2.44-3.77 mM), p.R2336H and 
p.G3990V transfected cells had EC50 values that were statistically significantly reduced to 
0.91 mM (95% CI 0.80-1.27 mM; P=0.0003) and 1.41 mM (95% CI 1.12-1.69 mM; 
P=0.0001) respectively.  The EC50 of cells transfected with the p.D3986E construct was 2.86 
mM (95% CI 2.23-3.48 mM), which was not statistically significantly different to wild type 
(P=0.23). 
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Ca2+ Imaging in transiently transfected HEK293 cells using pcRYR1 constructs 
Transient transfection of HEK293 cells was performed using the wild type, p.E3104K and 
p.V4849I constructs (arbitrarily chosen over p.R2355W) and the p.G3990V construct, which 
was selected to make a comparison between stable and transient transfection. 
Representative fluorescent traces produced from each construct are presented in Figure 2b.  
For each of the RYR1 variants, the caffeine dose-response curve was shifted to the left 
indicating an increase in sensitivity to caffeine (Figure 2c-e). HEK293 cells transiently 
transfected with each of the three variants produced a statistically significant decrease in 
EC50 response to caffeine as compared to wild type (EC50 for wild type, 4.1 mM, 95% CI 1.64-
5.95):  p.E3104K had an EC50 of 1.74 mM (95% CI 1.2-2.62; P=0.01 compared to wild type, 
n=7); p.G3990V had an EC50 of 1.25 mM (95% CI  0.76-1.62; P=0.01, n=6); p.V4849I had an 
EC50 of 1.71 mM (95% CI = 1.3-2.21; P=0.03,  n=7).   
 
Ca2+ Imaging in transiently transfected HEK293 cells using ptRYR1 constructs 
By the time we were in a position to start work on the remaining RYR1 variant to be 
characterized (p.R2355W), we had demonstrated that transient transfection produced similar 
results as stable transfection for p.G3990V, while cells expressing p.D3986E after stable 
transfection produced similar caffeine responses to cells expressing wild type RyR1. In order 
to exclude the possibility that the findings with p.D3986E were a consequence of variable 
expression we progressed to the pTUNE system for transient transfection in order to 
regulate RYR1 expression. HEK293 cells were transfected with wild type, p.R2355W and 
p.D3986E ptRYR1 variants.  Expression of RYR1 was induced using IPTG at a standard 
concentration of 25 µM.  Seventy-two hours post-transfection, cells were loaded with Fluo-4 
AM and exposed to incremental doses of caffeine.  Uninduced and untransfected cells were 
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indistinguishable from each other (data not shown) but cells that were transfected always 
responded in a concentration-dependent manner after induction.  Representative traces for 
the wild type, p.R2355W and p.D3986E constructs are shown in Figure 3b.  Concentration-
response curves (Figure 3c-d) illustrate the increased sensitivity of p.R2355W to caffeine 
(EC50 of 1.38 mM, 95% CI  0.02-2.3 mM) compared with wild type (3.8 mM, 95% CI  2.52-
5.4; P=0.048, n=4) but p.D3986E showed similar sensitivity to caffeine (EC50 4.67 mM, 95% 
CI 3.4-5.7 mM) as wild type (P=0.69).  
 
Discussion 
The work presented in this paper highlights several issues when attempting to classify RYR1 
variants for their potential pathogenicity in relation to malignant hyperthermia susceptibility. 
We have the most extensive phenotypically characterized MH patient resource in the world, 
but we found that segregation analysis using a method that enables data from multiple 
families to be simply combined was of limited value in defining the pathogenicity of RYR1 
variants. For the two variants that segregated with the MH susceptibility phenotype 
(p.E3104K, p.D3986E), the limited number of informative meioses precludes definitive 
conclusions for a condition demonstrating locus heterogeneity, where a SISA significance 
level of P < 0.001 would be analogous to a LOD score of >3 using linkage analysis. For the 
remaining variants, the incidence of genotype-phenotype discordance limits the use of SISA 
analysis.  
 
Our functional studies of recombinant RyR1 in the heterologous HEK293 system suggest, 
however, that the p.R2336H, p.R2355W, p.E3104K, p.G3990V and p.V4849I RYR1 variants 
produce a RyR1 protein with increased sensitivity to the agonist caffeine. Such gain of 
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function effects are consistent with a pathogenic role in malignant hyperthermia. On this 
basis, these variants meet the criteria of the European MH Group 10  for predictive diagnostic 
DNA screening as high-risk variants. These five variants have been identified in a total of 38 
families in the UK and their addition to the diagnostic panel of functionally characterized 
RYR1 and CACNA1S variants would increase the availability of diagnostic DNA screening in 
the UK MH population by 14%. These variants have been reported in at least a further 13 
families worldwide.  
 
The p.R2336H, p.R2355W and p.V4849I variants have been identified in other populations 
and previous attempts have been made to assess their functional consequences using 
primary cells (lymphoblastoid cells or skeletal myoblasts) derived from patients carrying the 
variant. Although this type of experimental model is included, with proviso, in the EMHG 
guidelines for functional analysis of RYR1 variants10, its use is controversial. As with 
recombinant HEK293 cells, expression of all the components of the excitation-contraction of 
adult skeletal muscle is not recapitulated in lymphoblastoid cells but, additionally, even in 
myotubes derived from patient skeletal myoblasts, the effects of the RYR1 variant under 
investigation cannot be isolated from those of other potentially pathogenic variants in the 
patientÕs genetic background.  
 
Lymphoblastoid cells obtained from patients carrying the p.R2336H variant only produced an 
MH phenotype when exposed to 4-chloro-m-cresol (4-CmC).  The response obtained from 
these cells when they were exposed to caffeine was similar to that of wild type familial 
control samples 23.  The reason for the apparent wild type response to caffeine in this system 
is not clear, especially given the positive result obtained using 4-CmC.  Additionally, the 6 
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families in the UK that possess this variant produced a typically strong reaction to caffeine 
during IVCT MH diagnosis 24.  The functional data presented in the recombinant system 
used in this study, however, provides clear evidence of an increased sensitivity to caffeine in 
cells expressing these variants. The data may suggest that the lymphoblastoid system 23 is 
unsuitable for functional experiments.   
 
Ducreux and colleagues 25 presented functional data from lymphoblastoid cells carrying the 
p.V4849I variant that showed responses to both caffeine and 4-CmC which were 
indistinguishable from wild type cells. Originally this result was attributed to the fact that the 
p.V4849I variant has also been identified in association with central core disease (CCD), a 
congenital myopathy also associated with RYR1 mutations that has been known to result in 
reduced calcium release from stores due to a higher passive calcium leak 26-28.  Additionally, 
the p.V4849I variant has been identified in a patient at low risk for MH susceptibility, leading 
to suggestions that this variant is not a pathogenic MH mutation 29. We suggest that our data 
obtained here using recombinant expression in HEK293 provide the clearest evidence to 
date that the p.V4849I variant has a pathogenic role in MH. No evidence of cores was found 
on histological examination of the probandsÕ muscle from each of our families found to carry 
this variant. 
 
The p.R2355W variant has been identified in 11 families worldwide and two studies 30,31 have 
presented functional data for this variant using primary cells isolated from a total of three 
families.  The results were indicative of a pathogenic MH variant and our data from 
recombinant expression in HEK293 confirm these findings.  
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Our results in HEK293 cells expressing the p.D3986E RYR1 variant were unexpected. 
Although we had a limited number of informative meioses in the 5 families where this variant 
is present there was no genotype-phenotype discordance. Analyses of IVCT responses in 
these families had previously suggested that the variant was associated with a relatively 
ÒstrongÓ phenotype 24. We initially used a pcRYR1 construct to stably transfect HEK293 cells 
and found no difference in caffeine sensitivity between cells expressing p.D3986E and those 
expressing wild type RyR1. In order to test the possibility that variable expression of RyR1 
p.D3986E in stably transfected cells might influence the caffeine responses, we carried out 
further experiments where we transiently transfected HEK293 cells using the inducible 
pTUNE vector to ensure equivalent amounts of RyR1 protein in wild type and mutant cells. 
Again, the responses of cells expressing p.D3986E and those expressing wild type RyR1 
were similar. These functional studies suggest that either the p.D3986E variant does not 
alter the function of the RyR1 or any such changes require co-expression of proteins 
normally expressed in skeletal muscle but not HEK293 cells. 
 
We were also interested in exploring whether both stable and transient expression in 
HEK293 cells produce similar results for assessing the functional significance of RYR1 
variants. Caffeine sensitivity of the p.G3990V was determined using both methods of 
transfection. The EC50 values for 1.41 mM (stable) and 1.25 mM (transient) transfection were 
similar and both significantly different to the wild type cells transduced using the same 
method. The EC50 values for cells expressing wild type after transient (using either construct) 
or stable transfection were similar as were those for cells expressing p.D3986E after 
transient (pTUNE) or stable transfection. 
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Four of the RYR1 variants (p.R2336H, p.R2355W, p.G3990V and p.V4849I), which were 
associated with increased caffeine sensitivity in the HEK293 expression system, were found 
in families where segregation between the variant and the IVCT phenotype was incomplete 
(Table 1). Where possible we excluded genotyping errors in discordant individuals and also 
calculated the likelihood of false positive IVCT responses in each affected non-carrier and 
conclude that it is extremely unlikely that this is a satisfactory explanation. Similar 
conclusions have been drawn from previous studies of genotype-phenotype discordance 32. 
Our current data provide further evidence that more than one genetic factor is operating in at 
least a minority of MH families 33,34,24. Indeed, in one family where the p.V4849I variant was 
detected initially, in a non-carrier of p.V4849I, who had a positive IVCT, a second rare RYR1 
variant was found when the entire coding region of RYR1 was sequenced using deep 
resequencing. Deep resequencing did not detect a second RYR1 variant in IVCT positive 
non-carriers from two other families but this does not exclude variants in other, as yet 
unidentified, genes to be implicated in the MH susceptibility phenotype. Another possibility, 
which we consider unlikely, is that the RYR1 variants are not associated with MH 
susceptibility and the increased caffeine sensitivity in the HEK293 system is not 
representative of the functional effects of these variants in human skeletal muscle. 
 
In conclusion, we have confirmed that segregation analysis has limited utility in establishing 
likely pathogenicity of RYR1 variants associated with MH susceptibility. Our functional data 
meet published criteria for adding five variants (p.R2336H, p.R2355W, p.E3014K, p.G3990V 
and p.V4849I) to the genetic diagnostic panel for MH susceptibility and demonstrates 
equipoise among methods used to transfect and select cells. This thereby extends the 
availability of DNA diagnosis by 14% of MH families. We were unable to confirm the 
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functional significance of the p.D3986E RYR1 variant in MH susceptibility but this may reflect 
an inadequacy of the heterologous HEK293 expression system for analysing all RYR1 
variants that have affected IVCT phenotypes. 	
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Table 1. Summary of segregation analyses in malignant hyperthermia families where one of 
six recurrent RYR1 variants has been identified. Ò-Ò indicates that it was not possible to 
calculate a probability of segregation using the SISA method because there were affected 
individuals who were not carriers of the familial variant. 
	
	 RYR1	variant	
c.7007G>A,	
p.R2336H	
c.7063C>T,
p.R2355W	
c.9310G>A,	
p.E3104K	
c.11958C>G,	
p.D3986E	
c.11969G>T,	
p.G3990V	
c.14545G>A,	
p.V4849I	
No.	 of	 families	
segregating	
6	 6	 4	 5	 10	 5	
Total	 no.	 of	
informative	meioses	 in	
segregating	families	
9	 10	 5	 4	 10	 26	
No.	 of	 non-segregating	
families	
2	 1	 0	 0	 1	 3	
Probability	 of	
segregation	by	chance	
-	 -	 0.031	 0.0625	 -	 -	
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Figure Legends 
	
Figure 1.  
a. Representative western blot image of HEK293 cells stably transfected with wild type and 
mutant pcRYR1 constructs. Proteins were run on a 4-8% polyacrylamide gel and blotted 
overnight onto a PVDF membrane.  The membrane was probed for RyR1 using  a 
monoclonal antibody.   
1b. Representative traces of HEK293 cells stably transfected with wild type and mutant 
pcRYR1 constructs.  The response at each caffeine concentration is seen as a temporary 
increase in fluorescence.  The red arrows mark the time that each caffeine concentration 
was added to the well and instantly perfused off.  Wild type transfected cells did not reach a 
maximum response before the addition of 5 mM caffeine.  This was the same for cells 
transfected with the p.D3986E variant, however, cells transfected with both the p.R2336H 
and p.G3990V variants often reached a maximum response at caffeine concentrations as 
low as 2 mM. 
1c-f. Caffeine concentration-response curves for HEK293 cells stably transfected with wild 
type and mutant pcRYR1 constructs.  (A-C) Concentration response curve for each variant 
stably transfected into HEK293 cells plotted with wild type responses. Data are mean (SE), 
n= 6 experiments in each case). (D) Box plots of the EC50 values calculated for each 
experiment. The boxes represent the inter-quartile range with the median value represented 
as the horizontal line within the box: the whiskers define the range.  A two-tailed studentÕs t-
test showed a statistically significant reduction in EC50 as compared to wild type for 
p.R2336H and p.G3990V.  No statistical significance was seen between wild type and 
p.D3986E. ***P<0.001 
 
Figure 2 
a. Representative western blot image of HEK293 cells transiently transfected with wild type 
and mutant pcRYR1 cDNA constructs.  Proteins were run on a 4-8% polyacrylamide gel and 
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blotted overnight onto a PVDF membrane.  The membrane was probed for RyR1 using  a 
monoclonal antibody.   
b.  Representative traces of caffeine-induced calcium release of cells transiently transfected 
with wild type and mutant pcRYR1 cDNA constructs. All three of the mutant pcRYR1 
constructs produced a maximum response at lower caffeine concentrations than the 
equivalent wild type experiment.  All cells responded at 1mM caffeine but the response was 
greater in the cells expressing mutant RyR1.   
c-f  Caffeine concentration-response for HEK293 cells transiently transfected with wild type 
and mutant pcRYR1 constructs.  (A-C) Concentration response curve for each variant 
transiently transfected into HEK293 cells plotted with wild type responses. Data are mean 
(SE), n= 6 or 7 experiments in each case). (D) Box plots of the EC50 values calculated for 
each experiment. The boxes represent the inter-quartile range with the median value 
represented as the horizontal line within the box: the whiskers define the range.  A two-tailed 
studentÕs t-test showed a statistically significant reduction in EC50 as compared to wild type 
for each mutant. *P<0.05 
 
Figure 3 
a. Representative western blot image of HEK293 cells transiently transfected with 
pTUNERYR1 and induced with 25 µM IPTG.  The first lane is from transfected cells not 
induced with IPTG. Proteins were run on a 4-8% polyacrylamide gel and blotted overnight 
onto a PVDF membrane.  The membrane was probed for RyR1 using  a monoclonal 
antibody.   
b. Representative traces of HEK293 cells transfected with pTUNERYR1 constructs showing 
the release of calcium when exposed to incremental doses of caffeine. Wild type transfected 
cells responded minimally to 1mM caffeine and had an increasing response as the 
concentration of caffeine increased.  A maximum response appeared to be reached at 
around 8 mM caffeine. Cells transfected with p.D3986E responded in a similar way to wild 
type.  Cells transfected with p.R2355W reached a maximum response at around 4 mM 
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caffeine and tended to have a more exaggerated response at doses of caffeine lower than 
this. 
c-e. Caffeine concentration-response curves of cells transfected with p.R2355W or 
p.D3986E pTUNERYR1 constructs compared to wild type. (A-B) Concentration-response 
curve for each variant plotted with wild type responses. Data are mean (SE), n= 4 
experiments in each case). (C) Box plots of the EC50 values calculated for each experiment. 
The boxes represent the inter-quartile range with the median value represented as the 
horizontal line within the box: the whiskers define the range.  A two-tailed studentÕs t-test 
showed a statistically significant reduction in EC50 for p.R2355W as compared to wild type. 
*P<0.05 
Supplementary figure 1. 
Pedigrees of the seven malignant hyperthermia (MH) families where affected non-carriers of 
familial RYR1 variants were found. Squares represent males and circles females: a diagonal 
line through the symbol indicates the person is deceased. Black filled symbols with a letter 
ÒSÓ indicate an MH susceptible phenotype determined by in vitro contracture testing (IVCT). 
Green filled symbols with a letter ÒNÓ indicate an MH negative phenotype determined by 
IVCT. Unfilled symbols with a Ò?Ó indicate an individual who has not undergone IVCT. Where 
an individual has undergone genotyping for the familial RYR1 variant, the genotype is 
presented in capital letters under the individual: blue lettering indicates concordance 
between genotype and phenotype; red lettering indicates discordance. The red arrows 
identify the index case who had the clinical reaction. 
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Supplementary table 1. Evolutionary conservation of the nucleotide base and amino acid 
affected in the variants across species. All amino acids are maintained throughout various 
species.  The only discrepancy is the presence of a T residue instead of a C for the 
p.D3986E variant however the amino acid remains aspartic acid in the wild type sequence. 
 cDNA change (Protein change) 
c.7007 G 
(p.R2336) 
c.7063 C  
(p.R2355) 
c.9310 G 
(p.E3104) 
c.11958 C 
(p.D3986) 
c.11969 G 
(p.G3990) 
c.14545 G 
(p.V4849) 
S
p
e
c
ie
s
 
Human G (R) C (R) G (E) C (D) G (G) G (V) 
Pig G (R) C (R) G (E) C (D) G (G) G (V) 
Rabbit G (R) C (R) G (E) C (D) G (G) G (V) 
Mouse G (R) C (R) G (E) T (D) G (G) G (V) 
Chimp G (R) C (R) G (E) C (D) G (G) G (V) 
Dog G (R) C (R) G (E) C (D) G (G) G (V) 
	
Supplementary table 2. Evolutionary conservation of the nucleotide and amino acid affected 
in the variants across the human RYR isoforms. All amino acids are maintained throughout 
the three RyR isoforms in humans apart from the p.R2355 residue in RyR3 which has a 
lysine instead of arginine.  The overall importance of this particular change is unknown due 
to the slightly different roles these isoforms play in the different tissues they are expressed 
in.  Similarly to the mouse RYR1 sequence, the human RYR2 sequence has a T residue 
instead of the C residue seen at position c.11958 for the p.D3986E variant, however once 
again the aspartic acid residue is maintained in the wild type sequence. 
 cDNA change (Protein change) 
c.7007 G 
(p.R2336) 
c.7063 C  
(p.R2355) 
c.9310 G 
(p.E3104) 
c.11958 C 
(p.D3986) 
c.11969 G 
(p.G3990) 
c.14545 G 
(p.V4849) 
Is
o
fo
rm
s
 RYR1 G (R) C (R) G (E) C (D) G (G) G (V) 
RYR2 G (R) A (R) G (E) T (D) G (G) G (V) 
RYR3 G (R) A (K) G (E) C (D) G (G) G (V) 
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Supplementary table 3.  Amino acid properties and minor allele frequencies (MAFs) of the 
variants selected for study. Four of the missense variants under investigation result in a 
substitution of amino acid that has altered properties and may therefore result in a change in 
the structure and function of the overall protein.  Of the 6 selected variants, 2 possess no 
obvious changes (p.D3986E and p.V4849I). The MAFs are those reported for all populations 
included in the Exome Variant Server database (http://evs.g.s.washington.edu/EVS, last 
accessed 19.10.2016): a Ò-Ò indicates that the variant is not reported in the EVS.  
 
Residue Starting 
amino acid 
Substituted 
amino acid 
Charge Acid/basic Hydrophobic/ 
hydrophilic 
MAF % 
2336 Arginine Histidine No change 
(positive) 
No change 
(basic) 
Hydrophilic to 
neutral 
- 
2355 Arginine Tryptophan Positive to 
neutral 
Basic to 
neutral 
Hydrophilic to 
hydrophobic 
0.0154 
3104 Glutamic 
acid 
Lysine Negative to 
positive 
Acidic to 
basic 
No change 
(hydrophilic) 
- 
3986 Aspartic 
acid 
Glutamic acid No change 
(negative) 
No change 
(acidic) 
No change 
(hydrophilic) 
- 
3990 Glycine Valine No change 
(neutral) 
No change 
(neutral) 
Neutral to 
hydrophobic 
- 
4849 Valine Isoleucine No change 
(neutral) 
No change 
(neutral) 
No change 
(hydrophobic) 
- 
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